Clinical Trials

Leukemia, Leukemia, Myeloid, Acute

NCT03681561 2026-03-09

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Phase NA Not yet recruiting

54 enrolled

Lymphoid

Hodgkin Disease

NCT07454226 2026-03-06

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

30 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02974647 2026-02-27

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Phase 1 Active not recruiting

83 enrolled

Lymphoid

Lymphoma, Recurrence

NCT07025538 2026-02-23

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

Phase 1 Suspended

42 enrolled

Hematopoietic and Lymphatic System Neoplasm

NCT03514069 2026-02-19

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

60 enrolled

CNS

Glioblastoma, Glioma

NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

50 enrolled

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT07359859 2026-02-17

A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

40 enrolled

Graft vs Host Disease, Hematologic Neoplasms

NCT05592015 2026-02-10

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

30 enrolled

Leukemia, Large Granular Lymphocytic

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Phase 1 Active not recruiting

23 enrolled 18 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03120624 2026-02-04

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

34 enrolled 16 charts

Gynecologic

Endometrial Neoplasms

NCT03610971 2026-01-29

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

MyeloidOther hematologic neoplasm

24 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT07366801 2026-01-26

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

Phase 2/3 Recruiting

64 enrolled

Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07356245 2026-01-21

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

DermatologicLymphoidOther hematologic neoplasm

44 enrolled

Graft vs Host Disease, Leukemia, Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06768476 2026-01-16

AML

Phase 1 Active not recruiting

12 enrolled

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT07219576 2026-01-13

PRISM

40 enrolled

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT03571321 2026-01-09

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

15 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04644211 2026-01-08

Ruxolitinib in Thrombocythemia and Polycythemia Vera

60 enrolled

Polycythemia Vera, Thrombocythemia, Essential

NCT07128381 2026-01-05

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

MyeloidOther hematologic neoplasm

66 enrolled

Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT07311746 2025-12-31

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

Phase 1/2 Not yet recruiting

36 enrolled

Leukemia, Prolymphocytic, T-Cell

NCT07249346 2025-12-24

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Classical hematologyOther hematologic neoplasm

124 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Leukemia, Myelomonocytic, Chronic

NCT05088356 2025-12-19

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

MyeloidOther hematologic neoplasm

60 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07283822 2025-12-16

Amping up With PemJAK

53 enrolled

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT07032727 2025-12-15

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

68 enrolled

Targeted Therapy

NCT06616155 2025-12-08

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 2/3 Active not recruiting

39 enrolled

Genitourinary

Prostatic Neoplasms

NCT03117751 2025-12-05

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

790 enrolled

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05010005 2025-12-03

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

70 enrolled

Recurrence, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Leukemia, Large Granular Lymphocytic

NCT06399029 2025-11-19

TRUX-LST

20 enrolled

Exanthema

NCT03274778 2025-11-18

Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells

Phase NA Withdrawn

Genitourinary

Prostatic Neoplasms

NCT03674047 2025-11-10

Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Phase EARLY_PHASE1 Recruiting

50 enrolled

Other Cancer

NCT04744116 2025-11-10

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

24 enrolled

Hematologic Neoplasms

NCT06291987 2025-11-05

MPN

18 enrolled

Myeloproliferative Disorders

NCT06128070 2025-10-31

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

LymphoidMyeloidOther hematologic neoplasm

40 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02131584 2025-10-27

Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia

10 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01787487 2025-10-09

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

121 enrolled

Myeloproliferative Disorders, Polycythemia Vera, Primary Myelofibrosis

NCT03017820 2025-10-08

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT05579769 2025-10-02

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

Phase 2 Terminated

3 enrolled 10 charts

Hematologic Neoplasms

NCT05745714 2025-09-16

HEM-iSMART C

26 enrolled